The Food and Drug Administration (FDA) approved the first gene therapy released in the U.S., Kymriah, also known as chimeric antigen receptor T-cell (CAR-T) therapy.
This document provides guidance on key performance indicators for denials management and revenue integrity, including calculations for denials rates and denials overturn ratios.
This policy is aimed at streamlining the audit process, protecting our patient’s confidentiality, ensuring prompt payment on audited accounts, and improving billing accuracy.